Extended comment period for IVDMIA guidance
This article was originally published in The Gray Sheet
Executive Summary
Stakeholders have until Oct. 17 to submit additional comments on FDA's draft guidance on in vitro diagnostic multivariate index assays. A 30-day comment period on the agency's revised draft, which would assert FDA enforcement over certain lab-developed tests, initially closed Aug. 27, but critics said there had been insufficient time to thoroughly evaluate the guidance's implications (1"The Gray Sheet" Sept. 3, 2007, p. 7)
You may also be interested in...
Lab Stakeholders Still Oppose FDA’s Multivariate Assay Policy
Laboratories are urging FDA to once again rework, if not abandon, its proposal to actively regulate certain lab-developed tests, while diagnostics companies are split on the issue
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.